Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF April 8, 2016 | Archived Issues

Recognition for Danoff, Murrell and Noah

Physician News

Dudley Danoff, MD, discussed his new book before a large crowd at the Medical Library, Zuri A. Murrell, MD, spoke to a church congregation about colorectal cancer, and Mark S. Noah, MD, will become the local governor of the American College of Physicians.

» Read more


Meetings and Events


Grand Rounds

Click here to view upcoming grand rounds.


Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - April 2016 (PDF)  


Milestones

Do you know of a significant event in the life of a medical staff member? Please let us know, and we'll post these milestones in Medical Staff Pulse. Also, feel free to submit comments on milestones, and we'll post the comments in the next issue. Click here to submit your milestones and comments.

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

FDA Warns About Opioids, Diabetes Medications

Pharmacy Focus

The U.S. Food and Drug Administration has issued warnings about safety issues with the entire class of opioid pain medicines and with Type 2 diabetes medicines containing saxagliptin and alogliptin.

FDA: All Opioids Have Safety Issues

The U.S. Food and Drug Administration has issued a warning about safety issues with the entire class of opioid pain medicines, including potentially harmful interactions with antidepressants and migraine medications, adrenal insufficiency and decreased sex hormone levels.

The FDA is requiring changes to the labeling of all opioid medications to warn about these risks.

The FDA has more information.

FDA: Some Type 2 Diabetes Medicines May Increase Risk of Heart Failure

An FDA safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.

As a result, the FDA is adding new warnings to the drug labels about this safety issue.

The FDA has more information.